| Req ID | Category | Intent | Legal Status | Name | Subdomain(s) | Context | Conditions | Confidence |
|---|---|---|---|---|---|---|---|---|
| #Q001 | administrative | operational | recommended | Guidance on Implementation | drinking water | Specific guidance related to the implementation of drinking water guidelines should be obtained from the appropriate drinking water authority in the affected jurisdiction. | When implementing the drinking water guidelines. | high |
| #Q002 | monitoring | operational | recommended | Source Water Characterization | drinking water | Utilities should characterize their source water to assess PFOA concentrations. | high | |
| #Q003 | monitoring | health | recommended | Monitoring Frequency for Exceedances | drinking water | In source waters where PFOA is present at levels exceeding the proposed MAC, quarterly monitoring of surface water and semi-annual monitoring of groundwater should be conducted. | Applies where PFOA is present at levels exceeding the proposed MAC. | high |
| #Q004 | monitoring | treatment | guidance | Enhanced Monitoring for GAC Systems | drinking water | Utilities that use a GAC system for PFOA removal may want to enhance monitoring of the treated water in order to assess the performance of the GAC system and to determine the timing of the regeneration. | Applies to utilities that use a GAC system for PFOA removal. | high |
| #Q005 | monitoring | operational | guidance | Reduced Monitoring Criteria | drinking water | Utilities may consider reduced monitoring when they have data indicating that PFOA does not occur in the source water. | When data indicates that PFOA does not occur in the source water. | high |
| #Q006 | monitoring | health | guidance | Monitoring for Other PFAAs (AFFF Contamination) | drinking water | However, if the main source of groundwater contamination is suspected to be from the use of AFFF, utilities may want to consider monitoring for other perfluorinated alkyl acids (PFAAs; i.e., shorter chain compounds such as perfluorobutanoic acid and perfluorobutane sulfonate). | Applies if the main source of groundwater contamination is suspected to be from the use of AFFF. | high |
| #Q007 | monitoring | operational | mandatory | Isotope-labelled Internal Standards Usage | drinking water | In addition, the use of isotope-labelled internal standards is a standard practice and must be used in the analysis of PFAS. | During the analytical quantification of PFAS. | high |
| #Q008 | operational | operational | recommended | Contamination Avoidance in Clean-up | drinking water | Care should be taken to avoid contamination of the extract or losses of PFASs during the clean-up procedures. | During sample extraction and clean-up procedures prior to instrumental determination. | high |
| #Q009 | operational | operational | recommended | Avoidance of Fluoropolymer Materials | drinking water | Contacts with such laboratory materials and products during analysis of PFOA should be avoided | Pertains to fluoropolymers (e.g., PTFE) during laboratory analysis. | high |
| #Q010 | operational | operational | recommended | Avoidance of Glassware for Sampling | drinking water | ISO method 25101 and EPA Method 537 recommended against the use of glassware for sampling due to the potential adsorption of PFOA on the walls | During collection and storage of water samples intended for PFOA analysis. | high |
| #Q011 | operational | operational | recommended | Sample Storage and Preservation Constraints | drinking water | The storage and sample preservation steps prior to the instrumental analysis should prevent changes in composition of the sample matrix and the concentration of the analyte | Prior to instrumental analysis. | high |
| #Q012 | monitoring | treatment | mandatory | GAC Breakthrough Monitoring | drinking water | Close monitoring of PFOA breakthrough (treatment objective) is necessary for efficient operation of GAC unit. | When utilizing a Granular Activated Carbon (GAC) unit for treatment. | high |
| #Q013 | treatment | treatment | recommended | Residential Device Usage Suggestion | drinking water | Generally, it is not recommended that drinking water treatment devices be used to provide additional treatment to municipally treated water. | Applies to municipal water connections (residential level). | high |
| #Q014 | treatment | treatment | recommended | Certified Treatment Devices Usage | drinking water | Health Canada does not recommend specific brands of drinking water treatment devices, but it strongly recommends that consumers use devices that have been certified by an accredited certification body as meeting the appropriate NSF International (NSF)/American National Standards Institute (ANSI) drinking water treatment unit standards. | When consumers select a residential drinking water treatment device. | high |
| #Q015 | treatment | treatment | recommended | Point-Of-Use Limitation for RO Systems | drinking water | RO systems should only be installed at POU as the water they have treated may be corrosive to internal plumbing components. | Applies to Reverse Osmosis (RO) residential systems. | high |
| #Q016 | treatment | health | recommended | NSF/ANSI Standard 61 Certification Requirement | drinking water | Health Canada strongly recommends that homeowners ensure that these systems are constructed using materials certified to NSF/ANSI Standard 61 (NSF/ANSI, 2014). | For ion exchange or residential treatment systems. | high |
| #Q017 | monitoring | operational | recommended | Residential Pre-installation Water Testing | drinking water | Before a treatment device is installed, the water should be tested to determine general water chemistry and verify the presence and concentration of PFOA. | Prior to installation of a residential treatment device. | high |
| #Q018 | monitoring | treatment | recommended | Residential Device Effectiveness Verification | drinking water | Periodic testing by an accredited laboratory should be conducted on both the water entering the treatment device and the finished water to verify that the treatment device is effective. | For residential treatment devices in use. | high |
| #Q019 | monitoring | operational | mandatory | PFAS Analysis Quality Control Procedures | drinking water | In order to generate accurate data, quality control (QC) procedures (matrix spikes, duplicates, spike-recovery experiments, surrogate recovery checks) are critical. | During the trace quantitation of PFASs in environmental water samples. | high |
| #Q020 | operational | operational | recommended | SPE Device Contamination Testing | drinking water | The U.S. EPA (2009a) recommends that SPE devices be tested prior to using them for analysis to ensure that there is no contamination of the sample. | Prior to using Solid Phase Extraction (SPE) devices for analysis. | high |
| #Q021 | design | treatment | mandatory | GAC System Design and Operation | drinking water | In order to achieve a PFOA concentration below 0.2 µg/L, the GAC system must be specifically designed and appropriately operated for PFOA removal in drinking water. | When utilizing Granular Activated Carbon (GAC) for PFOA removal to levels below 0.2 µg/L. | high |
| #Q022 | operational | operational | mandatory | RO Concentrate Disposal | other | RO rejects a significant portion of the influent water as contaminant-rich brine, and the concentrate discharge must be disposed of appropriately. | When utilizing Reverse Osmosis (RO) treatment systems. | high |
| #Q023 | operational | operational | mandatory | RO Post-Treatment Corrosion Control | drinking water | The removal of contaminants can cause mineral imbalances that could increase the corrosive nature of the treated water. In most cases, post-treatment corrosion control measures need to be taken. | Post-treatment following Reverse Osmosis (RO) to mitigate potential corrosivity. | high |
| #Q024 | treatment | treatment | guidance | Ion Exchange Pre-treatment Requirement | drinking water | If an ion exchange system is used, the water may need to be filtered through a GAC filter to remove any chlorine or chloramine (if connected to a treated water supply) from the water before it reaches the resin. | When using an ion exchange system connected to a treated water supply containing chlorine or chloramine. | high |
| #Q025 | operational | operational | guidance | Analytical Sample Pre-treatment Filtration | drinking water | Prior to a SPE, a sample pre-treatment (filtration) may be required to facilitate extraction or to remove matrix constituent that will interfere with analyses. | Prior to a Solid Phase Extraction (SPE). | high |
| #Q026 | treatment | treatment | guidance | Residential RO Influent Pre-treatment | drinking water | A consumer may need to pre-treat the influent water to reduce fouling and extend the service life of the membrane. | When using a residential Reverse Osmosis (RO) system. | high |
| #Q027 | operational | operational | recommended | Nanofiltration Pilot and Full-Scale Testing | drinking water | Testing of the selected NF membrane for PFOA removal at both pilot- and full-scale is an important step for utilities when considering this treatment process. | When a utility is considering the implementation of nanofiltration (NF) treatment. | high |
| #Q028 | design | treatment | recommended | NF Membrane Selection Criteria | drinking water | Since the size exclusion is an important mechanism for PFASs rejection by NF membranes, consideration should be taken to select membranes with MWCO smaller than the size of PFOA. | During the selection of nanofiltration (NF) membranes for PFAS rejection. | high |
| #Q029 | treatment | treatment | guidance | Treatment Selection for Long-Chain PFAS | drinking water | If long-chain PFASs are detected in the drinking water sources, the utility may consider the implementation of treatments such as GAC. | When long-chain PFASs are detected in drinking water sources. | high |
| #Q030 | treatment | treatment | guidance | Treatment Selection for Short-Chain PFAS | drinking water | However, utilities that have shorter chain PFASs in their raw water source may choose to implement RO or NF. | When shorter chain PFASs are detected in the raw water source. | high |
| #Q031 | operational | treatment | mandatory | GAC Media Replacement | drinking water | When the adsorption capacity of the GAC is exhausted, it must be removed from the contactor and replaced with fresh or reactivated carbon. | When the adsorption capacity of the GAC media is exhausted. | high |
| #Q032 | operational | treatment | mandatory | Residential Device Maintenance and Replacement | drinking water | Devices can lose removal capacity through use and time and need to be maintained and/or replaced. | Applies to residential treatment devices. | high |
| Req ID | Category | Intent | Legal Status | Name | Subdomain(s) | Limit Type | Limit Value | Context | Conditions | Confidence |
|---|---|---|---|---|---|---|---|---|---|---|
| #P001 | chemical | health | guideline | PFOA | drinking water | MAC | 0.0002 mg/L | A maximum acceptable concentration (MAC) of 0.0002 mg/L (0.2 µg/L) is proposed for PFOA in drinking water. | Applies to the general population | high |
| #P002 | chemical | health | guideline | PFOA | drinking water | MAC | 0.2 µg/L | A maximum acceptable concentration (MAC) of 0.0002 mg/L (0.2 µg/L) is proposed for PFOA in drinking water. | Applies to the general population | high |
| #P003 | operational | reporting | recommended | Surface water monitoring frequency | drinking water | requirement | 4 per year | Quarterly monitoring of surface water should be conducted. | In source waters where PFOA is present at levels exceeding the proposed MAC | high |
| #P004 | operational | reporting | recommended | Groundwater monitoring frequency | drinking water | requirement | 2 per year | Semi-annual monitoring of groundwater should be conducted. | In source waters where PFOA is present at levels exceeding the proposed MAC | high |
| #P005 | chemical | health | guideline | PFOA Health-Based Value (Cancer) | drinking water | requirement | 0.03 mg/L | The HBV for PFOA in drinking water is 0.03 mg/L (rounded). | Based on Leydig cell tumours in male rats | high |
| #P006 | chemical | reporting | mandatory | PFOA MRL (UCMR3) | drinking water | requirement | 20 ng/L | UCMR3 stipulates that an MRL of 20 ng/L (0.02 µg/L) for PFOA must be achieved and reported. | When using Method 537 ver. 1.1 | high |
| #P007 | chemical | health | guideline | PFOA Health-Based Value (Non-cancer) | drinking water | requirement | 0.0002 mg/L | Using this TDI, the HBV for drinking water can be calculated as follows: The HBV for PFOA in drinking water is 0.0002 mg/L. | Based on hepatocellular hypertrophy in rats | high |
| #P008 | chemical | health | guideline | Tolerable Daily Intake (TDI) - Cancer | drinking water | requirement | 0.003 mg/kg bw per day | Using the calculated PODHEQ, the cancer TDI was calculated as follows: The TDI for PFOA is 0.003 mg/kg bw per day. | Based on PODHEQ associated with the NOAEL for Leydig cell tumours in male rats | high |
| #P009 | chemical | health | guideline | Tolerable Daily Intake (TDI) - Non-cancer | drinking water | requirement | 0.000025 mg/kg bw per day | Using the calculated PODHEQ, the non-cancer TDI was calculated as follows: The non-cancer TDI for PFOA is 0.000025 mg/kg bw per day. | Based on PODHEQ calculated for hepatocellular hypertrophy in rats | high |
| #P010 | chemical | reporting | guidance | MDL for PFOA (EPA Method 537) | drinking water | requirement | 1.7 ng/L | The MDL for PFOA is 1.7 ng/L (0.0017 µg/L) using Method 537 ver. 1.1. | high | |
| #P011 | chemical | reporting | guidance | LCMRL for PFOA (EPA Method 537) | drinking water | requirement | 5.1 ng/L | The Lowest Concentration Minimum Reporting Level (LCMRL) is 5.1 ng/L (0.0051 µg/L) using Method 537 ver. 1.1. | high | |
| #P012 | chemical | reporting | guidance | LOQ for PFOA (3M Method ETS-8-154.3) | drinking water | requirement | 25 ng/L | The method (ETS-8-154.3) has a limit of quantitation (LOQ) of 25 ng/L (0.025 µg/L) for PFOA. | high | |
| #P013 | operational | treatment | recommended | GAC Replacement Frequency | drinking water | requirement | 3 - 6 months | Studies indicated that PFOA was successfully removed from drinking water when a frequent regeneration or replacement (3 to 6 months) of the GAC was performed. | For utilities specifically targeting PFOA removal | high |
| #P014 | chemical | reporting | guidance | ISO Method 25101 concentration range | drinking water, other | requirement | 10 - 10,000 ng/L | ISO Method 25101 was found to be appropriate for determination of PFOA levels in unfiltered samples of drinking water, groundwater and surface water with concentrations in the range of 10 - 10,000 ng/L (0.01 - 10 µg/L). | Unfiltered samples of drinking water, groundwater and surface water | high |
| #P015 | chemical | reporting | guidance | PFOA limit of detection (LOD) - SPE/LC-MS/MS | drinking water | requirement | 0.28 ng/L | A study reported a limit of detection (LOD) (signal-to-noise [S/N] = 3:1) of 0.28 ng/L... using an SPE followed by LC-MS/MS for analyzing PFOA in surface water. | Signal-to-noise (S/N) = 3:1 | high |
| #P016 | chemical | reporting | guidance | PFOA limit of quantitation (LOQ) - SPE/LC-MS/MS | drinking water | requirement | 0.94 ng/L | A study reported... an LOQ (S/N= 10:1) of 0.94 ng/L using an SPE followed by LC-MS/MS for analyzing PFOA in surface water. | Signal-to-noise (S/N) = 10:1 | high |
| #P017 | chemical | reporting | guidance | PFOA limit of detection (LOD) - SPE/LC-MS/MS (Villaverde-de-Saa) | drinking water | requirement | 0.03 ng/L | Reported by Villaverde-de-Saa et al. (2015) using SPE followed by LC-MS/MS. | Calculated as 3 times the standard deviation | high |
| #P018 | chemical | reporting | guidance | PFOA limit of quantitation (LOQ) - SPE/LC-MS/MS (Villaverde-de-Saa) | drinking water | requirement | 0.11 ng/L | Reported by Villaverde-de-Saa et al. (2015) using SPE followed by LC-MS/MS. | Calculated as 10 times the standard deviation | high |
| #P019 | chemical | reporting | guidance | PFOA limit of quantitation (LOQ) - Direct Injection (Furdui et al.) | drinking water | requirement | 0.5 ng/L | Reported by Furdui et al. (2008) for samples from the Great Lakes. | Signal-to-noise [S/N] = 10:1 | high |
| #P020 | chemical | reporting | guidance | PFOA detection limit (DL) - Finished Water (Quebec) | drinking water | requirement | 0.3 - 0.6 ng/L | Reported detection limits for finished water in Quebec province monitoring. | 500 mL sample analyzed | high |
| #P021 | chemical | reporting | guidance | PFOA detection limit (DL) - Untreated Water (Quebec) | drinking water | requirement | 0.5 - 1.0 ng/L | Reported detection limits for untreated water in Quebec province monitoring. | 250 mL analyzed sample | high |
| #P022 | chemical | health | guideline | PFOA Provisional Health Advisory (US EPA) | drinking water | requirement | 0.4 µg/L | The U.S. EPA Office of Water indicates a Provisional Health Advisory (PHA) of 0.4 μg/L (0.0004 mg/L) for PFOA. | Derived from a BMDL10 of 0.46 mg/kg bw per day for increased maternal liver weight in mice | high |
| #P023 | chemical | health | guideline | PFOA preliminary health-based guidance (New Jersey) | drinking water | requirement | 0.04 µg/L | The New Jersey Department of Environmental Protection derived a preliminary health-based guidance of 0.04 μg/L. | Derived from NOAEL of 1.6 mg/kg bw per day in rats | high |
| #P024 | chemical | health | guideline | PFOA health risk limit (HRL) (Minnesota) | drinking water | requirement | 0.3 µg/L | The Minnesota Department of Health derived a health risk limit (HRL) of 0.3 μg/L (0.0003 mg/L). | Based on increased liver weight in monkeys | high |
| #P025 | chemical | health | guideline | PFOA drinking water guideline (UK HPA) | drinking water | requirement | 10 µg/L | A drinking water guideline of 10 μg/L (0.01 mg/L) was derived by the UK Health Protection Agency. | Based on a TDI of 3,000 ng/kg bw per day | high |
| #P026 | chemical | health | guideline | PFOA Tolerable Daily Intake (TDI) (EFSA) | drinking water | requirement | 1500 ng/kg bw per day | The CONTAM panel under EFSA derived a TDI of 1,500 ng/kg bw per day (1.5 μg/kg bw per day). | Based on a BMDL10 of 0.3 mg/kg bw per day in rats for liver effects | high |
| #P027 | chemical | health | guideline | PFOA Tolerable Daily Intake (TDI) - UK HPA | drinking water | requirement | 3000 ng/kg bw per day | A drinking water guideline of 10 μg/L was derived by the UK Health Protection Agency based on a TDI of 3,000 ng/kg bw per day. | As established by the UK Committee on Toxicity | high |
| #P028 | chemical | health | guideline | PFOA Drinking Water Allocation Factor | drinking water | requirement | 20 % | The default allocation factor for drinking water of 20% is used for PFOA as a floor value when water is a minor contributor to exposure. | Applicable for the general population | high |
| #P029 | design | treatment | guidance | PFOA Treatment Goal - Residential Reverse Osmosis | drinking water | treatment_goal | < 0.05 µg/L | Available data suggests that residential reverse osmosis can achieve treated PFOA concentrations below 0.05 µg/L. | For residential scale applications | high |
| Req ID | Category | Name | Context | Confidence |
|---|---|---|---|---|
| #D001 | PFOA | The term "PFOA" may refer to the free acid (C8HF15O2; CAS number 335-67-1; 414.07 g/mol) or its conjugate base (C8F15O2-; CAS number 45285-51-6). | high | |
| #D002 | APFO | The term APFO (ammonium perfluorooctanoate) refers to the ammonium salt (C8F15O2- NH4+; CAS number 3825-26-1), its principal salt | high | |
| #D003 | K+PFOA | K+PFOA refers to the potassium salt (CAS number 2395-00-8). | high | |
| #D004 | probable link | The "probable link" defined by the Science Panel means that "given the available scientific evidence, it is more likely than not that among class members a connection exists between PFOA exposure and a particular human disease." | high | |
| #D005 | suitable BMDL | A suitable BMDL is defined as a lower 95% confidence limit estimate of dose corresponding to a 1-10% level of risk over background levels. | high | |
| #D006 | AFFF | aqueous film-forming foam | high | |
| #D007 | ALT | alanine transaminase | high | |
| #D008 | APFO | ammonium perfluorooctanoate | high | |
| #D009 | BMD | benchmark dose | high | |
| #D010 | BMDL | lower confidence limit on the benchmark dose | high | |
| #D011 | BMDL 10 | lower 95% confidence limit on the benchmark dose for a 10% response | high | |
| #D012 | BV | bed volume | high | |
| #D013 | CAS | Chemical Abstracts Service | high | |
| #D014 | CI | confidence interval | high | |
| #D015 | CSAF | chemical specific adjustment factor | high | |
| #D016 | DI | direct injection | high | |
| #D017 | DL | detection limit | high | |
| #D018 | EBCT | empty bed contact time | high | |
| #D019 | EPA | Environmental Protection Agency (U.S.) | high | |
| #D020 | ESI | electrospray ionization | high | |
| #D021 | GAC | granular activated carbon | high | |
| #D022 | GD | gestational day | high | |
| #D023 | GM | geometric mean | high | |
| #D024 | HBV | health-based value | high | |
| #D025 | HPLC | high performance liquid chromatography | high | |
| #D026 | ISO | International Standard Association | high | |
| #D027 | IT | ion-trap | high | |
| #D028 | LC | liquid chromatograph | high | |
| #D029 | LOAEL | lowest-observed-adverse-effect level | high | |
| #D030 | LOD | limit of detection | high | |
| #D031 | LOQ | limit of quantitation | high | |
| #D032 | LLE | liquid-liquid extraction | high | |
| #D033 | MAC | maximum acceptable concentration | high | |
| #D034 | MDL | method detection limit | high | |
| #D035 | MGD | mammary gland development | high | |
| #D036 | MG/D | million gallons per day | high | |
| #D037 | MOA | mode of action | high | |
| #D038 | MRL | minimum reporting level | high | |
| #D039 | MS/MS | tandem mass spectrometry | high | |
| #D040 | NF | nanofiltration | high | |
| #D041 | NOAEL | no-observed-adverse-effect level | high | |
| #D042 | NOM | natural organic matter | high | |
| #D043 | PAC | powdered activated carbon | high | |
| #D044 | PBPK | Physiologically-based pharmacokinetic | high | |
| #D045 | PEFT | polytetrafluoroethylene | high | |
| #D046 | PFA | perfluoroalkyl | high | |
| #D047 | PFAA | perfluorinated alkyl acid | high | |
| #D048 | PFAS | perfluoroalkyl substance | high | |
| #D049 | PFCA | long-chain perfluorocarboxylic acids | high | |
| #D050 | PFOA | perfluorooctanoic acid | high | |
| #D051 | PFOS | perfluorooctane sulfonate | high | |
| #D052 | PND | postnatal day | high | |
| #D053 | POD | point of departure | high | |
| #D054 | POD HEQ | human-equivalent points-of-departure | high | |
| #D055 | PTFE | polytetrafluoroethylene | high | |
| #D056 | RBF | river bank filtration | high | |
| #D057 | RO | reverse osmosis | high | |
| #D058 | SPE | solid phase extraction | high | |
| #D059 | TDI | tolerable daily intake | high | |
| #D060 | TDS | total diet study | high | |
| #D061 | UCMR3 | third Unregulated Contaminant Monitoring Rule (U.S.) | high | |
| #D062 | WAX | weak anion exchange | high | |
| #D063 | LCMRL | Lowest Concentration Minimum Reporting Level | high | |
| #D064 | alum | aluminum sulfate | high | |
| #D065 | MWCO | membrane molecular weight cut-off | high | |
| #D066 | CNTs | CNTs are carbon molecules composed of carbon lattices that can take the form of tubes. | high | |
| #D067 | Chitosan | Chitosan is a natural polysaccharide based on the shells of crustaceans. | high | |
| #D068 | Molecular imprinting | Molecular imprinting is a technique where specific sites for target compounds are constructed on a polymer so that specific adsorbates are recognized in the sorption process. | high | |
| #D069 | ENFMs | ENFMs are prepared by electrospinning nanofibers of polymer or polymer composite materials to create membranes of non-woven fibers with diameters ranging from several hundreds to tens of nanometers | high | |
| #D070 | AKUF | toxicokinetic portion of the interspecies uncertainty factor | high | |
| #D071 | ADUF | toxicodynamic component | high | |
| #D072 | Vd | volume of distribution, which is the theoretical volume of blood in which the amount of a chemical would need to be uniformly distributed to produce the observed blood concentration | high | |
| #D073 | MGD score | MGD is scored on a 1-4 subjective, age-appropriate developmental scale based on the number of primary ducts and large secondary ducts, lateral side branching, appearance of budding from the ductal tree, and longitudinal outgrowth of the epithelia. | high | |
| #D074 | pKa | acid dissociation constant | high | |
| #D075 | Kow | octanol:water partition coefficient | high | |
| #D076 | PFCAs | perfluorocarboxylic acids | high | |
| #D077 | PFAs | perfluoroalkyls | high | |
| #D078 | PAPs | polyfluoroalkyl phosphate surfactant | high | |
| #D079 | PAA | di-perfluoro-alkyloxy-amino-acid | high | |
| #D080 | S-PACs | superfine PACs | high | |
| #D081 | AOPs | Advanced oxidation processes (AOPs) have been developed for removal of contaminants that are resistant to more typical chemical oxidation treatment processes. They include the use of appropriate combinations of ultraviolet (UV) light, chemical oxidants and catalysts (e.g., ozone, hydrogen peroxide, titanium dioxide) to generate highly reactive radicals, such as hydroxyl radicals, which are strong oxidants and react rapidly and non-selectively with organic contaminants. | high | |
| #D082 | MIPs | chitosan-based molecularly imprinted polymers | high | |
| #D083 | L-FABP | rat liver fatty acid binding protein | high | |
| #D084 | PHA | Provisional Health Advisory | high | |
| #D085 | HRL | health risk limit | high | |
| #D086 | HED | human equivalent dose | high | |
| #D087 | RfD | reference dose | high | |
| #D088 | C8 Health Project | The C8 Health Project is the largest study of a population exposed to PFAAs in drinking water, containing residents of Ohio and West Virginia communities surrounding the DuPont Washington Works plant. | high | |
| #D089 | C8 Science Panel | The C8 Science Panel was convened as a result of a class action settlement against DuPont, and is composed of independent epidemiologists jointly selected by lawyers for the community and DuPont. | high | |
| #D090 | PFASs | Particle-bounded volatile perfluoroalkyl substances | high | |
| #D091 | PFAAs | perfluorinated alkyl acids | high | |
| #D092 | PACl | polyaluminium chloride | high | |
| #D093 | RSSCTs | Rapid small-scale column tests | high | |
| #D094 | DOC | dissolved organic carbon | high | |
| #D095 | MF | microfiltration | high | |
| #D096 | UF | ultrafiltration | high | |
| #D097 | gfd | gallons per square foot per day | high | |
| #D098 | PEEK | polyetheretherketone | high | |
| #D099 | NMR | nuclear magnetic resonance | high | |
| #D100 | TOF | time-of-flight | high | |
| #D101 | OATs | organic ion transporters | high | |
| #D102 | BAFs | bioaccumulation factors | high | |
| #D103 | BCFs | bioconcentration factors | high | |
| #D104 | S/N | signal-to-noise | high | |
| #D105 | RBF | River bank filtration (RBF) is a drinking water treatment method where surface water flows through the subsurface sand and gravel layers of the bank or bed of a river to extraction wells and contaminants are removed through the processes of filtration, sorption, dilution and biodegradation. | high | |
| #D106 | ln 2 | natural log of 2 | high | |
| #D107 | T1/2 | half-life of a compound | high | |
| #D108 | TEBs | terminal end buds | high | |
| #D109 | TDs | terminal ducts | high | |
| #D110 | WY | Wyeth-14,643 | high | |
| #D111 | CL | CL is clearance in animals and humans (e.g., mL/kg bw per day). | high | |
| #D112 | POU | point-of-use (POU) | high | |
| #D113 | POE | point-of-entry (POE) | high | |
| #D114 | AST | aspartate transaminase (AST) | high | |
| #D115 | GGT | gamma glutamyl transpeptidase (GGT) | high | |
| #D116 | ADHD | attention deficit/hyperactivity disorder (ADHD) | high | |
| #D117 | AIC | Akaike information criterion [AIC] | high | |
| #D118 | CDW | Federal-Provincial-Territorial Committee on Drinking Water | high | |
| #D119 | IARC | International Agency for Research on Cancer | high | |
| #D120 | PFBA | perfluorobutanoic acid | high | |
| #D121 | PFBS | perfluorobutane sulfonate | high | |
| #D122 | PFHpA | perfluoroheptanoic acid | high | |
| #D123 | PFHxS | perfluorohexanesulfonate | high | |
| #D124 | PFHxA | perfluorohexanoic acid | high |